The cell therapy is intended for the treatment of progressive glioblastoma multiforme. Credit: /

Chimeric Therapeutics has launched a new Phase IB clinical trial of CHM 1101 (CLXT CAR T) cell therapy to treat patients with recurrent or progressive glioblastoma multiforme (GBM).

The study will evaluate the safety and efficacy of CHM 1101 in patients with the deadliest primary brain cancer.

It intends to enrol patients at the Sarah Cannon Research Institute (SCRI) at St David’s South Austin Medical Center in Austin, Texas, US.

The two-part Phase IB study will determine a recommended Phase II dose and includes Part A and Part B.

Part A of the study will enrol three to six patients and test for the highest dose at the City of Hope Cancer Centre, and Part B will enrol 12 to 26 additional patients.

Chimeric will also evaluate the safety and activity from the CHM 1101 clinical programme late this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chimeric Therapeutics CEO and managing director Jennifer Chow said: “This multi-centre trial will enable us to more rapidly advance the development of CHM 1101 with recruitment across multiple clinical trial sites and also prepare us to accelerate the next phase of development if supported by the clinical results.”

Upon completion of the Part B dose examination arm, Chimeric plans to design and initiate a registration trial along with global regulatory feedback.

In the initial two dose cohorts carried out at the City of Hope, Phase IA investigator-initiated trial of CHM 1101 demonstrated safety with ~70% disease stability.

Chimeric Therapeutics chief medical officer Jason Litten said: “GBM continues to represent an important unmet medical need and the early clinical results from the City of Hope trial provide support that CHM 1101 may improve outcomes for GBM patients.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.